                         SEQUENCE LISTING

<110>  THE REGENTS OF THE UNIVERSITY OF MICHIGAN
 
<120>  TARGETING MELANOCORTIN 3 RECEPTOR FOR TREATMENT/PREVENTION OF 
       EATING, METABOLISM, AND/OR EMOTIONAL DISORDERS

<130>  UM-37762.601

<150>  US 62/902,088
<151>  2019-09-18

<150>  US 62/863,388
<151>  2019-06-19

<160>  15    

<170>  PatentIn version 3.5

<210>  1
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic

<400>  1

Tyr Val Met Gly His Phe Arg Trp Asp Phe Gly 
1               5                   10      


<210>  2
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Xaa=Nle

<400>  2

Xaa Asp Pro Pro Ala Arg Trp Lys 
1               5               


<210>  3
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Xaa=Nle

<400>  3

Xaa Asp Trp Pro Ala Arg Trp Lys 
1               5               


<210>  4
<400>  4
000


<210>  5
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic

<400>  5

His Phe Arg Trp 
1               


<210>  6
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic

<400>  6

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val 
1               5                   10              


<210>  7
<211>  22
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic

<400>  7

Ala Glu Lys Lys Asp Glu Gly Pro Tyr Arg Met Glu His Phe Arg Trp 
1               5                   10                  15      


Gly Ser Pro Pro Lys Asp 
            20          


<210>  8
<211>  23
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic

<400>  8

Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe Asp Pro Arg Asn Ser 
1               5                   10                  15      


Ser Ala Gly Gly Ser Ala Gln 
            20              


<210>  9
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic

<400>  9

Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe Gly 
1               5                   10          


<210>  10
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic

<400>  10

Tyr Val Met Gly His Phe Arg Trp Asp Arg Phe 
1               5                   10      


<210>  11
<211>  38
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic

<400>  11

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 
1               5                   10                  15      


Arg Arg Pro Val Lys Val Tyr Pro Asn Gly Ala Glu Asp Ser Ala Glu 
            20                  25                  30          


Ala Phe Pro Leu Glu Phe 
        35              


<210>  12
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa = any of the Xaa1 Tetrapeptide MC3R agonists in Table 3

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa = any of the Xaa4 Tetrapeptide MC3R agonists in Table 3

<400>  12

Xaa Arg Phe Xaa 
1               


<210>  13
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic

<400>  13

Arg Arg Phe 
1           


<210>  14
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic

<400>  14

His Arg Phe 
1           


<210>  15
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic

<400>  15

Arg Arg Phe Ala 
1               


